Merck has finalized a $6.7 billion acquisition of Terns Pharmaceuticals, significantly enhancing its cancer drug pipeline, particularly in the area of hematology with the addition of TERN-701, a novel candidate for chronic myeloid leukemia (CML). This strategic move comes as Merck seeks to diversify its offerings ahead of the impending patent expiry of Keytruda, its flagship oncology treatment. The acquisition has led to a surge in Terns’ stock price and positions Merck favorably in the competitive landscape of cancer therapeutics.